The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.

Lesions with occult CNV or with some classic CNV component are permissible. However, if classic CNV (well-demarcated hyperfluorescence boundaries in the early phase of the fluorescein angiogram) is present, the area of classic CNV must be <50% of the total lesion size.

The total area of CNV (including both classic and occult components) encompassed within the lesion must be >=50% of the total lesion area.

The total lesion area must be <=12 disc areas (DA) in size.

Best corrected visual acuity, using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, of 20/40 to 20/320 (Snellen equivalent) in the study eye

Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0

History of vitrectomy surgery in the study eye

History of submacular surgery or other surgical intervention for AMD in the study eye

Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals)

Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either >=50% of the total lesion area or >=1 disc area in size

Subfoveal fibrosis or atrophy in the study eye

CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia

Retinal pigment epithelial tear involving the macula in the study eye

Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either: (1) Require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition, or (2) If allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 24-month study period

History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications

Current treatment for active systemic infection

History of allergy to fluorescein, not amenable to treatment

Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center

Inability to comply with study or follow up procedures

Gender

Both

Ages

50 Years and older

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects